Lead article on FDA regulation of ophthalmic drugs

Dr. Novack published the lead article in the June 2024 issue of the American Journal of Ophthalmology. In this article, he showed a time line of key U.S. FDA registration and the availability of ocular hypotensive drugs (i.e., drugs that decrease elevated intraocular pressure) to patients and their doctors. He concludes that “Concomitant with public […]

Dr. Novack cited in New York Times article on safety of ophthalmic medications

Dr. Novack was cited in an article in the New York Times on 4 April 2024 regarding the safety of ophthalmic medications. He noted that eye-care products have a higher risk of health harm because they’re applied directly to the eye. Also, that manufacturing and storing these products has to maintain sterility and stability.

Dr. Novack Podcast on new glaucoma drugs

Calling attention to a podcast from Wilmer Eye – Diagnosis Glaucoma. Drs. Mona Kaleem and Harry Quigley talk with Dr. Gary Novack about the Drug Development Process for new pharmacological treatments for glaucoma. In episode 43, discussed are the development and FDA approval process of eye drop medications for glaucoma. Towards the end of the […]

Dr. Novack selected to be fellow of AOPT

Dr. Novack was selected to be a fellow of the Association for Ocular Pharmacology and Therapeutics. The Association for Ocular Pharmacology and Therapeutics is a global organization for scientists and individuals from all disciplines related to ocular pharmacology and its therapeutic applications.  Fellows of AOPT are nominated by their peers based upon service to the […]

Dr. Novack gives lecture at University of Michigan

Dr. Novack gave a lecture at the Kellogg Eye Center of the School of Medicine at the University of Michigan. The topic was “Contaminated Eye Drops: What is going on”? He described the ongoing issue with contamination and infection, what to do for patients, and the impact of this issue on the larger field of […]

ARVO 2023 – New Orleans

In this, my 40th ARVO annual meeting, I was able to share science, thoughtful discussions, and social encounters with friends and colleagues. While we are no longer on the beach in shorts, the spirit of Sarasota can still be seen in respectful, impactful discourse.

Compounding of Low-Concentration Atropine for Myopia Control

I call attention to this paper of mine just published in Eye & Contact Lens together with colleagues Drs. Kathryn Richdale, Erin Tomiyama and Mark Bullimore – a survey of the variability of atropine formulation, sterility and stability testing and storage requirements for compounded low dose atropine for myopia prevention. https://pubmed.ncbi.nlm.nih.gov/36083169/

Dr. Novack honored by American Academy of Ophthalmology

Gary D. Novack, Ph..D. was honored by the American Academy of Ophthalmology (AAO). In the AAO’s honors for its 2022 Annual Meeting, Dr. Novack was cited by its Secretariat for his work on the Academy’s journal, Ophthalmology Glaucoma. Dr. Novack serves as both an author and reviewer for this journal.

Gary Novack presents talk on new glaucoma drugs

Dr. Gary Novack presented an invited talk on “Why are there not more new glaucoma drugs” at the August meeting of the Glaucoma Research Society. The Glaucoma Research Society is a public interest, non-profit scientific association of outstanding glaucoma researchers that provides a forum to discuss and stimulate compelling or innovative research to prevent glaucoma-related […]